JP2008503475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008503475A5 JP2008503475A5 JP2007516725A JP2007516725A JP2008503475A5 JP 2008503475 A5 JP2008503475 A5 JP 2008503475A5 JP 2007516725 A JP2007516725 A JP 2007516725A JP 2007516725 A JP2007516725 A JP 2007516725A JP 2008503475 A5 JP2008503475 A5 JP 2008503475A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- matrix
- poly
- pharmaceutically acceptable
- esters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 6
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- -1 carboxyvinyl esters Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229920006187 aquazol Polymers 0.000 description 1
- 239000012861 aquazol Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960000967 memantine hydrochloride Drugs 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229920003179 starch-based polymer Polymers 0.000 description 1
- 239000004628 starch-based polymer Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58124204P | 2004-06-17 | 2004-06-17 | |
| PCT/US2005/021260 WO2006009769A1 (en) | 2004-06-17 | 2005-06-16 | Modified release formulation of memantine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008503475A JP2008503475A (ja) | 2008-02-07 |
| JP2008503475A5 true JP2008503475A5 (enExample) | 2011-02-24 |
Family
ID=34972465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516725A Pending JP2008503475A (ja) | 2004-06-17 | 2005-06-16 | メマンチンの放出が改変された製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (9) | US8039009B2 (enExample) |
| EP (1) | EP1781261A1 (enExample) |
| JP (1) | JP2008503475A (enExample) |
| CN (1) | CN1968684A (enExample) |
| AU (1) | AU2005265031A1 (enExample) |
| BR (1) | BRPI0512177A (enExample) |
| CA (1) | CA2569015A1 (enExample) |
| EA (1) | EA011446B1 (enExample) |
| IL (1) | IL179991A0 (enExample) |
| MX (1) | MXPA06014587A (enExample) |
| WO (1) | WO2006009769A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| US20060002999A1 (en) | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| TW200616608A (en) * | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| US8058291B2 (en) | 2005-04-06 | 2011-11-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of CNS-related conditions |
| US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| EA013474B1 (ru) * | 2005-06-16 | 2010-04-30 | Форест Лэборэтериз, Инк. | Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина |
| US20070077310A1 (en) * | 2005-10-03 | 2007-04-05 | University Of Tennessee Research Foundation | Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species |
| US20070141148A1 (en) * | 2005-11-30 | 2007-06-21 | Merz Pharma Gmbh & Co. Kgaa | Neramexane MR matrix tablet |
| EP2040676A2 (en) * | 2006-07-06 | 2009-04-01 | Forest Laboratories, Inc. | Orally dissolving formulations of memantine |
| GB0623897D0 (en) * | 2006-11-30 | 2007-01-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutical composition of memantine |
| US20080182908A1 (en) * | 2007-01-25 | 2008-07-31 | Vinita Umashankar Vyas | Pharmaceutical compositions comprising memantine |
| AU2008227465B2 (en) | 2007-03-22 | 2014-02-06 | Magceutics, Inc. | Magnesium compositions and uses thereof |
| TW200916091A (en) * | 2007-06-08 | 2009-04-16 | Merz Pharma Gmbh & Amp Co Kgaa | Neramexane for the treatment of nystagmus |
| EP2170310A4 (en) * | 2007-06-29 | 2010-06-23 | Orchid Chemicals & Pharm Ltd | FAST-DISSOLVING COMPOSITIONS OF MEMANTINE HYDROCHLORIDE |
| EP2583669A1 (en) | 2007-10-10 | 2013-04-24 | Rubicon Research Private Limited | Taste-masked orally disintegrating tablets of memantine hydrochloride |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| WO2010112221A1 (en) | 2009-04-03 | 2010-10-07 | Synthon B.V. | Pharmaceutical compositions comprising memantine |
| KR20120100964A (ko) | 2009-09-30 | 2012-09-12 | 바이타패스 제네틱스 인코포레이티드 | 개인용 보조인자 및 사용 방법 |
| JP5885668B2 (ja) * | 2009-12-02 | 2016-03-15 | アダマス ファーマシューティカルズ， インコーポレイテッド | アマンタジン組成物および使用方法 |
| MX2013004123A (es) | 2010-10-12 | 2013-12-16 | Univ Johns Hopkins | Composiciones antitusigenas que comprenden memantina. |
| US20140004189A1 (en) * | 2011-01-25 | 2014-01-02 | Cadila Healthcare Limited | Modified release pharmaceutical compositions memantine |
| TR201104108A2 (tr) | 2011-04-27 | 2011-08-22 | Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. | Uzatılmış salımlı memantin tablet. |
| MX2014000419A (es) | 2011-07-15 | 2014-09-22 | Nusirt Sciences Inc | Composicones y metodos para modular trayectorias metabolicas. |
| US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| RU2488388C1 (ru) * | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
| CN103417483B (zh) * | 2012-05-25 | 2017-09-12 | 杭州赛利药物研究所有限公司 | 盐酸美金刚缓释干混悬剂及其制备方法 |
| WO2014015047A1 (en) | 2012-07-17 | 2014-01-23 | The General Hospital Corporation | Compositions and methods to treat neurodegenerative diseases |
| ES2623176T3 (es) | 2012-08-16 | 2017-07-10 | Teva Pharmaceutical Industries Ltd. | Composición farmacéutica de memantina |
| RU2559776C2 (ru) * | 2012-08-20 | 2015-08-10 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления |
| UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
| BR112015010947A2 (en) | 2012-11-13 | 2018-06-05 | Nusirt Sciences, Inc. | compositions and methods for increasing energy metabolism. |
| JP2016505023A (ja) | 2013-01-15 | 2016-02-18 | ニューサート サイエンシーズ， インコーポレイテッド | 肺の状態の処置 |
| SG11201507046UA (en) | 2013-03-15 | 2015-10-29 | Nusirt Sciences Inc | Leucine and nicotinic acid reduces lipid levels |
| WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| PL3027171T3 (pl) * | 2013-07-30 | 2020-08-24 | Gilead Connecticut, Inc. | Formulacja inhibitorów syk |
| TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
| CA2939833A1 (en) | 2014-02-27 | 2015-09-03 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
| US10350165B2 (en) | 2014-12-12 | 2019-07-16 | Ojai Energetics Pbc | Methods and systems for forming stable droplets |
| CA2970651C (en) | 2014-12-12 | 2020-09-29 | Ojai Energetics Pbc | Microencapsulated cannabinoid compositions |
| CA2973944C (en) * | 2015-01-26 | 2019-07-30 | Daiichi Sankyo Company, Limited | Solid composition of pyrrole carboxamide |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CN116270646A (zh) | 2015-10-16 | 2023-06-23 | 艾伯维公司 | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CN105412047A (zh) * | 2015-12-03 | 2016-03-23 | 烟台东诚药业集团股份有限公司 | 一种骨架型盐酸美金刚缓释胶囊及其制备方法 |
| MX2018015583A (es) | 2016-06-15 | 2019-05-16 | Ojai Energetics Pbc | Metodos y composiciones para reducir el estres oxidativo. |
| AU2017286656A1 (en) | 2016-06-15 | 2019-01-17 | Ojai Energetics Pbc | Methods and compositions for potentiating stem cell therapies |
| RU2623865C1 (ru) * | 2016-06-29 | 2017-06-29 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина |
| RU2654713C1 (ru) * | 2016-06-29 | 2018-05-22 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина |
| WO2018200885A1 (en) | 2017-04-26 | 2018-11-01 | Neurocentria, Inc. | Magnesium compositions and methods of use |
| CA3072764A1 (en) | 2017-08-24 | 2019-02-28 | Adamas Pharma, Llc | Amantadine compositions, preparations thereof, and methods of use |
| WO2019126531A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
| WO2020067887A1 (en) | 2018-09-24 | 2020-04-02 | Erasmus University Medical Center Rotterdam | Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses |
| WO2020131921A1 (en) | 2018-12-18 | 2020-06-25 | Ojai Energetics Pbc | Cannabinoid compositions for virtual and augmented reality experiences |
| WO2020161719A1 (en) * | 2019-02-06 | 2020-08-13 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Combination therapy for treatment of brain disorders |
| AU2020225455A1 (en) | 2019-02-22 | 2021-09-09 | Kronos Bio, Inc. | Solid forms of condensed pyrazines as Syk inhibitors |
| WO2020208398A1 (es) | 2019-04-09 | 2020-10-15 | Laboratorios Bagó S.A. | Composición farmacéutica en polvo con memantina y donepecilo para utilizar en el tratamiento de la enfermedad de alzheimer |
| US10966989B2 (en) * | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
| US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
| US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
| US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
| US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
| US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
| US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
| US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
| CU24720B1 (es) | 2020-11-24 | 2024-10-09 | Centro De Neurociencias De Cuba | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
| US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
| US20240082204A1 (en) * | 2022-09-09 | 2024-03-14 | Zyvran Pharmaceuticals | Treatment composition for mild cognitive impairment and dementia |
| US12097189B1 (en) | 2024-02-09 | 2024-09-24 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7305644A (enExample) * | 1972-04-20 | 1973-10-23 | ||
| DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| SI8710406B (sl) | 1987-03-11 | 1998-08-31 | Lek | Tablete s podaljšanim delovanjem na osnovi hidroksipropilmetilceluloze z veliko molsko maso in postopek za njihovo pripravo |
| US5506231A (en) * | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| US5334618A (en) * | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| DE10299048I2 (de) * | 1989-04-14 | 2006-07-13 | Merz Pharma Gmbh & Co Kgaa | Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie |
| US5614560A (en) * | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| US5582837A (en) * | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| DE4225730C2 (de) * | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
| MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
| AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| ATE302597T1 (de) | 1997-06-06 | 2005-09-15 | Depomed Inc | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
| US6071966A (en) * | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
| UA61962C2 (uk) * | 1997-06-30 | 2003-12-15 | Мерц Фарма Гмбх Унд Ко. Кгаа | Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування |
| US6413556B1 (en) * | 1999-01-08 | 2002-07-02 | Sky High, Llc | Aqueous anti-apoptotic compositions |
| SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| US6444702B1 (en) * | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
| MXPA03005130A (es) | 2000-12-07 | 2004-12-06 | Neuromolecular Inc | Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda. |
| US20040102525A1 (en) * | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
| US20050191349A1 (en) * | 2003-12-31 | 2005-09-01 | Garth Boehm | Galantamine formulations |
| WO2005065645A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
| EP1715843A1 (en) * | 2004-01-29 | 2006-11-02 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions |
| US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| EA013474B1 (ru) * | 2005-06-16 | 2010-04-30 | Форест Лэборэтериз, Инк. | Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина |
| US20090247644A1 (en) * | 2008-03-28 | 2009-10-01 | Forest Laboratories Holdings Limited | Memantine formulations |
-
2005
- 2005-06-16 WO PCT/US2005/021260 patent/WO2006009769A1/en not_active Ceased
- 2005-06-16 US US11/155,330 patent/US8039009B2/en active Active
- 2005-06-16 JP JP2007516725A patent/JP2008503475A/ja active Pending
- 2005-06-16 BR BRPI0512177-9A patent/BRPI0512177A/pt not_active IP Right Cessation
- 2005-06-16 MX MXPA06014587A patent/MXPA06014587A/es not_active Application Discontinuation
- 2005-06-16 AU AU2005265031A patent/AU2005265031A1/en not_active Abandoned
- 2005-06-16 CN CNA200580019805XA patent/CN1968684A/zh active Pending
- 2005-06-16 EP EP05760426A patent/EP1781261A1/en not_active Withdrawn
- 2005-06-16 EA EA200700049A patent/EA011446B1/ru not_active IP Right Cessation
- 2005-06-16 CA CA002569015A patent/CA2569015A1/en not_active Abandoned
-
2006
- 2006-12-11 IL IL179991A patent/IL179991A0/en unknown
-
2011
- 2011-09-15 US US13/233,381 patent/US20120004318A1/en not_active Abandoned
-
2012
- 2012-09-14 US US13/618,014 patent/US20130012593A1/en not_active Abandoned
-
2013
- 2013-07-23 US US13/948,438 patent/US20130310460A1/en not_active Abandoned
-
2014
- 2014-03-28 US US14/228,944 patent/US20140213659A1/en not_active Abandoned
-
2015
- 2015-01-28 US US14/607,526 patent/US20150148427A1/en not_active Abandoned
- 2015-05-27 US US14/722,538 patent/US20150258031A1/en not_active Abandoned
-
2016
- 2016-07-20 US US15/215,456 patent/US10660868B2/en not_active Expired - Lifetime
-
2020
- 2020-04-17 US US16/852,158 patent/US20200268685A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2485942C2 (ru) | Бупропиона гидробромид и его терапевтические применения | |
| JP5592902B2 (ja) | 治療薬の徐放性組成物 | |
| JP2009545560A5 (enExample) | ||
| JP2004534031A (ja) | 心臓および循環器疾患の治療および予防を目的とする一日一回の治療のための経口制御放出医薬組成物 | |
| EP2114380A1 (en) | Modified release pharmaceutical composition and a process of making the same | |
| US9387178B2 (en) | Modified release tranexamic acid formulation | |
| WO2006082523A2 (en) | Pharmaceutical sustained release composition of metformin | |
| CN104114163A (zh) | 治疗心血管疾病的方法 | |
| CN101193638A (zh) | 用于良性前列腺肥大疗法的组合 | |
| US20040033262A1 (en) | Sustained release pharmaceutical composition of a cephalosporin antibiotic | |
| EP3220898A1 (en) | Pharmaceutical bead formulations comprising dimethyl fumarate | |
| AU2004258732B2 (en) | Sustained release formulation for venlafaxine hydrochloride | |
| WO2004016250A1 (en) | Sustained release pharmaceutical composition of a cephalosporin antibiotic | |
| JP2010521437A5 (enExample) | ||
| AU2004315136A1 (en) | Extended release coated microtablets of venlafaxine hydrochloride | |
| WO2011072481A1 (zh) | 一种颗粒组合控释片 | |
| AU2014237934B2 (en) | Controlled release pharmaceutical dosage forms | |
| WO2003084514A1 (en) | Controlled release pharmaceutical compositions of carbidopa and levodopa | |
| JP2002536318A5 (enExample) | ||
| CN1720026A (zh) | 含有阿夫唑嗪的缓释组合物 | |
| US20050281873A1 (en) | Universal controlled-release composition | |
| JP5826456B2 (ja) | コーティングされていない分離したユニットおよび延長放出マトリクスを含む制御放出配合物 | |
| KR20130121717A (ko) | 위체류 약물전달 시스템을 이용한 서방성 제제 | |
| JP2007510654A (ja) | 分極した酸素原子を有するポリマーを含むマトリクスからの正に荷電した薬理学的活性分子の徐放 | |
| JP2024512069A5 (enExample) |